A single-nucleotide polymorphism in the 3'-UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer

Oncotarget

Volumn 7, Issue 14, 2016, Pages 18984-18998

  Wang, Wenmiao ^a,b   Yuan, Peng ^a   Yu, Dianke ^a   Du, Feng ^a   Zhu, Anjie ^a   Li, Qing ^a   Zhang, Pin ^a   Lin, Dongxin ^a   Xu, Binghe ^a  

^a CANCER HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

3' untranslated regions; FABP4; Genetic variant; Prognosis; Triple negative breast cancer

Indexed keywords

FATTY ACID BINDING PROTEIN 4; 3' UNTRANSLATED REGION; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN;

3' UNTRANSLATED REGION; ADIPOCYTE; ADULT; ALLELE; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER TISSUE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FABP4 GENE; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OBESITY; PROTEIN EXPRESSION; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; GENETICS; GENOTYPE; METABOLISM; PATHOLOGY; PROGNOSIS;

3' UNTRANSLATED REGIONS; ADIPOCYTES; ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE-FREE SURVIVAL; FATTY ACID-BINDING PROTEINS; FEMALE; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84975476300     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7920     Document Type: Article

References (41)

1. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007; 109:1721-1728.
2. Irvin WJ Jr, Carey LA. What is triple-negative breast cancer? Eur J Cancer. 2008; 44:2799-2805.
3. Perez EA, Moreno-Aspitia A, Aubrey Thompson E, Andorfer CA. Adjuvant therapy of triple negative breast cancer. Breast Cancer Res Treat. 2010; 120:285-291.
4. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D. Locoregional relapse and distant metastasis in conservatively managed triple-negative early-stage breast cancer. J Clin Oncol. 2006; 24:5652-57.
5. Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014; 232:142-50.
6. Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA. TNBCtype: A subtyping tool for triplenegative breast cancer. Cancer Inform. 2012; 11:147-156.
7. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, et al. From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA. 2003; 100:7737-7742.
8. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6:259-269.
9. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6:857-866.
10. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449:682-688.
11. Svoboda M, Sana J, Redova M, Navratil J, Palacova M, Fabian P, Slaby O, Vyzula R. MiR-9, a MYC/MYCNactivated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 2010; 12:247-256.
12. Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, Shapiro CL, Huebner K. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One. 2013; 8:e55910.
13. Svoboda M, Sana J, Redova M, Navratil J, Palacova M, Fabian P, Slaby O, Vyzula R. MiR-34b is associated with clinical outcomein triple-negative breast cancer patients. Diagn Pathol. 2012; 7:31. doi:10.1186/1746-1596-7-31.
14. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993; 75:855-62.
15. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433:769-773.
16. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200family promotes EMT and invasion in cancer cells. EMBO J. 2008; Rep.9: 582-589.
17. Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, et al. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol. 2011; 12:377-386.
18. Yang R, Schlehe B, Hemminki K, Sutter C, Bugert P, Wappenschmidt B, Volkmann J, Varon R, Weber BH, Niederacher D, Arnold N, Meindl A, Bartram CR, et al. A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. Breast Cancer Res Treat. 2010; 121:693-702.
19. Wang L, Liu W, Jiang W, Lin J, Jiang Y, Li B, Pang D. A miRNA binding site single-nucleotide polymorphism in the 3'-UTR region of the IL23R gene is associated with breast cancer. PLoS One. 2012; 7:e49823.
20. Sung H, Jeon S, Lee KM, Han S, Song M, Choi JY, Park SK, Yoo KY, Noh DY, Ahn SH, Kang D. Common genetic polymorphisms of microRNA biogenesis pathway genes and breast cancer survival. BMC Cancer. 2012; 12:195-207.
21. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumour chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13:2329-2334.
22. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010; 7:e1000279.
23. Bhushan B, Khalyfa A, Spruyt K, Kheirandish-Gozal L, Capdevila OS, Bhattacharjee R, Kim J, Keating B, Hakonarson H, Gozal D. Fatty-acid binding protein 4 gene polymorphisms and plasma levels in children with obstructive sleep apnea. Sleep Med. 2011; 12:666-71.
24. Vasudevan S, Tong Y, Steitz JA. Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation. Science. 2007; 318:1931-4.
25. Scheja L, Makowski L, Uysal KT, Wiesbrock SM, Shimshek DR, Meyers DS, Morgan M, Parker RA, Hotamisligil GS. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/-mice. Diabetes. 1999; 48: 1987-1994.
26. Hertzel AV, Hellberg K, Reynolds JM, Kruse AC, Juhlmann BE, Smith AJ, Sanders MA, Ohlendorf DH, Suttles J, Bernlohr DA. Identification and characterization of a small molecule inhibitor of fatty acid binding proteins. J. Med. Chem. 2009; 52: 6024-6031.
27. Harjes U, Bridges E, McIntyre A, Fielding BA, Harris AL. Fatty acid-binding protein 4, a point of convergence for angiogenic and metabolic signaling pathways in endothelial cells. J Biol Chem. 2014; 289:23168-76.
28. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumour growth. Nat Med. 2011; 17:1498-503.
29. Hancke K, Grubeck D, Hauser N, Kreienberg R, Weiss JM. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat. 2010; 119:367-377.
30. Kim S, Lee Y, Koo JS. Differential expression of lipid metabolism related proteins in different breast cancer subtypes. PLoS One. 2015; 10:e0119473.
31. Housa D, Housova J, Vernerova Z, Haluzik M. Adipocytokines and cancer. Physiol Res. 2006; 55:233-244.
32. Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Rel Cancer. 2007; 14:189-206.
33. Lorincz A, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer. 2006; 13:279-292.
34. Pan H, Gray RG, on behalf of the Early Breast Cancer Trialists' Collaborative Group; Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000 patients in 70 trials. Program and abstracts of the 2014 American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract 503.
35. Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, Navarro Rosenblatt D, Thune I, Vieira R, Norat T. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014; 25:1901-1914.
36. Chlebowski RT, Blackburn GL. Final survival analysis from the randomized Women's Intervention Nutrition Study (WINS) evaluating dietary intervention as adjuvant breast cancer therapy. Program and abstracts of the San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, Texas. Abstract S5-08.
37. Wang A, Aragaki AK, Tang JY, Kurian AW, Manson JE, Chlebowski RT, Simon MS, Desai PM, Wassertheil-Smoller S, Liu S, Kritchevsky S, Wakelee HA, et al. Statin use and all-cancer mortality: Prospective results from the Women's Health Initiative. Program and abstracts of the 2015 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2015; Chicago, Illinois. Abstract 1506.
38. Takeyama N, Itoh Y, Kitazawa Y, Tanaka T. Altered hepatic mitochondrial fatty acid oxidation and ketogenesis in Endotoxic rats. Am J Physiol. 1990; 22: 498-505.
39. Deyarmin B, Kane JL, Valente AL, van Laar R, Gallagher C, Shriver CD, Ellsworth RE. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Ann Surg Oncol. 2013; 20:87-93.
40. Liu C, Zhang F, Li T, Lu M, Wang L, Yue W, Zhang D. MirSNP, a database of polymorphisms altering miRNA target sites, identifies miRNA-related SNPs in GWAS SNPs and eQTLs. BMC Genomics. 2012; 13:661.
41. Shaffer JP. Controlling the false discovery rate with constraints: the Newman-Keuls test revisited. Biometrical J. 2007; 49:136-143.